Theranos Settles Suits Accusing Startup of Duping Hedge Fund
- Accord resolves Partners Management Fund’s Delaware suits
- Theranos seeking to end other litigation over testing scandal
This article is for subscribers only.
Theranos Inc. agreed to settle an early investor’s claims that the embattled blood-testing firm misrepresented its performance and technology in order to raise more than $96 million in funding.
Partner Management Fund LP will drop two lawsuits related to the startup’s fumbling of blood tests, Theranos officials said Monday in an emailed statement. Terms of the accord weren’t released.